Bayer bullish on sales

Bayer (BAYRY) believes that it will increase sales by at least 8% per year until 2016 due to robust sales of new products. It forecasts peak sales of $10.4B for five new drugs.

The products are Xarelto, Eylea, Stivarga, Xofigo and Adempas.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs